Litifilimab Hits 24-Week Endpoint Bar in AMETHYST Phase 2 Cutaneous Lupus Trial
JAAD publishes 24-week randomized phase 2 AMETHYST data on litifilimab, the BDCA2-targeting antibody, in cutaneous lupus erythematosus. Effect sizes await full-text review.